1 BACKGROUND Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for hematological diseases. The HSCT and the subsequent period of immunodeficiency entail a risk of severe adverse events, including infections, relapse, and graft-versus-host disease (GvHD).1 The stem cell graft is known to play an essential role in the complications mentioned above.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Anna
Contact Anna, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack